King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...